The Leadership and Administrative Core (LAC) will serve to integrate and enhance the research conducted by the SPORE projects and cores, as well as the Career Development faculty and investigators supported through the Developmental Research Program, through the application of general administrative support and the facilitation of communication and data dissemination. The Core will also provide the formal links between the following entities: (1) All investigators comprising the Pacific Northwest (PNW) SPORE in prostate cancer;(2) Advisory Panels (e.g., External Advisory Board [EAB], Internal Advisory Board [lAB], etc.);(3) Review Panels evaluating Career Development and Developmental Research proposals;(4) Those institutional structures (e.g. FHCRC and other SPORE participatory sites) with laboratories and clinical facilities wherein occur the research and education components of the SPORE;and (5) Representatives of the National Cancer Institute (NCI). This Leadership and Administrative Core has the following Specific Aims:
Specific Aim 1. To provide oversight of all SPORE activities involving the independent research projects, the Career Development Program (CDP), the Developmental Research Program (DRP), the shared resource cores, and the parent institutions.
Specific Aim 2. To provide the organizational structure, based on a group of interacting committees, for supporting and evaluating the key objectives of the PNW SPORE.
Specific Aim 3. To organize and coordinate forums for interactions of the Executive Committee, Internal Advisory Board, and External Advisory Board.
Specific Aim 4. To provide efficient and effective fiscal management of grant funds.
Specific Aim 5. To communicate and consult with the NCI Project Officer(s) and staff in the preparation of required progress reports, publications lists, and regulatory documents.
Specific Aim 6. To develop and maintain virtual mechanisms that efficiently facilitates multi-institutional intra- and inter-SPORE interactions.
The ongoing successful functioning of the PNW prostate cancer SPORE is highly dependent upon the effective and efficient operations provided by the Administrative Core. The Core will continue to be the hub for SPORE-related management, education, and communication within and across the four SPORE institutions, and it is vital for carrying out the overall scientific and translational mission of the SPORE.
|Uo, T; Dvinge, H; Sprenger, C C et al. (2016) Systematic and functional characterization of novel androgen receptor variants arising from alternative splicing in the ligand-binding domain. Oncogene :|
|Zhang, Ailin; Zhang, Jiawei; Plymate, Stephen et al. (2016) Classical and Non-Classical Roles for Pre-Receptor Control of DHT Metabolism in Prostate Cancer Progression. Horm Cancer 7:104-13|
|Lam, Hung-Ming; McMullin, Ryan; Nguyen, Holly et al. (2016) Characterization of an abiraterone ultraresponsive phenotype in castration-resistant prostate cancer patient-derived xenografts. Clin Cancer Res :|
|Faltermeier, Claire M; Drake, Justin M; Clark, Peter M et al. (2016) Functional screen identifies kinases driving prostate cancer visceral and bone metastasis. Proc Natl Acad Sci U S A 113:E172-81|
|Qu, Xiaoyu; Jeldres, Claudio; Glaskova, Lena et al. (2016) Identification of Combinatorial Genomic Abnormalities Associated with Prostate Cancer Early Recurrence. J Mol Diagn 18:215-24|
|Saranchova, Iryna; Han, Jeffrey; Huang, Hui et al. (2016) Discovery of a Metastatic Immune Escape Mechanism Initiated by the Loss of Expression of the Tumour Biomarker Interleukin-33. Sci Rep 6:30555|
|Shui, Irene M; Kolb, Suzanne; Hanson, Christi et al. (2016) Trichomonas vaginalis infection and risk of advanced prostate cancer. Prostate 76:620-3|
|Gulati, Roman; Cheng, Heather H; Lange, Paul H et al. (2016) Screening men at increased risk for prostate cancer diagnosis: Model estimates of benefits and harms. Cancer Epidemiol Biomarkers Prev :|
|Pritchard, Colin C; Mateo, Joaquin; Walsh, Michael F et al. (2016) Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer. N Engl J Med 375:443-53|
|Coleman, Daniel J; Van Hook, Kathryn; King, Carly J et al. (2016) Cellular androgen content influences enzalutamide agonism of F877L mutant androgen receptor. Oncotarget 7:40690-40703|
Showing the most recent 10 out of 323 publications